Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2020 | Update on biomarkers in urothelial cancer presented at ESMO 2020

Thomas Powles, MBBS, MCRP, Barts Cancer Institute, London, UK, gives an updated summary on biomarkers in urothelial cancer presented at ESMO 2020. Prof. Powles discusses five different biomarkers that are used for measuring PD-L1 expression. These include SP142, 22C3, tumor mutation burden (TMB), CD8 and transforming growth factor (TGF-β). Studies have suggested that positive data for the aforementioned biomarkers are yet to be confirmed within randomized, Phase III study. A key question for future study is whether the PD-L1 biomarker can be sandwiched together with other biomarkers to increase enrichment of patient immunity. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.